Implications of bevacizumab discontinuation in adults with recurrent glioblastoma.

@article{Anderson2014ImplicationsOB,
  title={Implications of bevacizumab discontinuation in adults with recurrent glioblastoma.},
  author={Mark Daniel Anderson and Mohamed Ali Hamza and Kenneth R. Hess and Vinay K. Puduvalli},
  journal={Neuro-oncology},
  year={2014},
  volume={16 6},
  pages={823-8}
}
BACKGROUND Patients with recurrent glioblastoma benefiting from bevacizumab are often treated indefinitely due to concerns regarding rebound tumor recurrence upon discontinuation. However, treatment is discontinued for reasons other than disease progression in a subset of these patients, the characteristics and outcomes of which are poorly defined. METHODS Of 342 adults with recurrent glioblastoma in our database treated with bevacizumab, 82 received treatment for ≥ 6 months; of these… CONTINUE READING